Search Results

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, announced that management will participate in the following upcoming investor conferences.

Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported financial results for the quarter ended March 31, 2024, and provided a corporate update.

Tempest Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 14,000 shares of its common stock under the Company’s 2023 Inducement Plan.

Tempest Therapeutics, Inc. announced that Stephen Brady, president and chief executive officer of Tempest, will present at the 44th Annual TD Cowen Healthcare Conference on Monday, March 4, 2024 at 9:10 a.m. ET.